All In Biotech

NDA 211158 · Amneal

Tigecycline

Tigecycline · Intravenous · Tetracycline-class Antibacterial

Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 2, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

23 Phase 3, 6 recruiting

FAERS reports

4,358

4,073 serious, 1,192 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ALL-CAUSE MORTALITY An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in tigecycline for injection-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable [see Indications and Usage (1.4) , Warnings and Precautions (5.1 , 5.2) and Adverse Reactions (6.1) ]. WARNING: ALL-CAUSE MORTALITY See full prescribing information for complete boxed warning. All-cause mortality was higher in patients treated with tigecycline for injection than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in...

What it is approved for

From the label in effect Dec 17, 2024.

Tigecycline is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections (1.1) Complicated intra-abdominal infections (1.2) Community-acquired bacterial pneumonia (1.3) Limitations of Use: Tigecycline for injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. (1.4) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Complicated Skin and Skin Structure Infections Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus ), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. 1.2 Complicated Intra-abdominal Infections Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus grp. (includes S....

Mechanism: Tigecycline is a tetracycline class antibacterial drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 2, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • TIGECYCLINE · TIGECYCLINE 50MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Tigecycline" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective638
  • off label use549
  • nausea302
  • drug resistance213
  • sepsis207
  • vomiting205
  • septic shock193
  • thrombocytopenia193
  • pathogen resistance172
  • product use in unapproved indication168
  • diarrhoea156
  • acute kidney injury153

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20068
200731
200863
200950
201037
201161
201271
201380
201479
2015151
2016107
2017216
2018241
2019404
2020360
2021419
2022332
2023417
2024518
2025413
2026298

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tigecycline (Tigecycline)

2024 spending

$2.4M

Beneficiaries

652

3,241 claims

Per beneficiary

$3,715

$19.85 per unit

View as table
YearSpending
2020$3,402,277
2021$3,640,666
2022$2,858,482
2023$3,491,734
2024$2,422,416

Part B: Tigecycline* (Tigecycline*) · HCPCS J3243

2024 spending

$40K

Beneficiaries

41

614 claims

Per beneficiary

$967

2024 ASP limit $0.63 per unit

View as table
YearSpending
2020$510,008
2021$318,211
2022$80,981
2023$48,843
2024$39,666

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 191 on PubMed

Sponsor: Amneal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.